Table 3.
Organ Failure Support, Myocarditis Treatment, Complications, and Outcome in ICU
| All Patients (N = 38) | MIS-A− (n = 13) | MIS-A+ (n = 25) | P Value | |
|---|---|---|---|---|
| Time in ICU, days | 6 (4-16) | 12 (7-30) | 5 (2-6) | <0.0001 |
| Cardiac arrest before ICU | 1 (3) | 1 (8) | 0 (0) | 0.3 |
| Organ failure support in ICU | ||||
| Dobutamine | 30 (79) | 12 (92) | 18 (72) | 0.2 |
| Norepinephrine | 23 (60) | 12 (92) | 11 (44) | 0.005 |
| Mechanical ventilation | 19 (50) | 11 (85) | 8 (32) | 0.005 |
| Time on mechanical ventilation, days | 15 (6-28) | 15 (8-35) | 11 (4-25) | 0.3 |
| Renal replacement therapy | 11 (29) | 8 (61) | 3 (12) | 0.003 |
| VA-ECMO | 16 (42) | 12 (92) | 4 (16) | <0.0001 |
| VA-ECMO under CPR | 4 (11) | 4 (31) | 0 (0) | 0.02 |
| Time on VA-ECMO, days | 7 (5-12) | 8 (6-12) | 5 (4-12) | 0.1 |
| Time from admission to VA-ECMO, days | 1 (0-1) | 0 (0-1) | 1 (0-5) | 0.4 |
| VV-ECMO | 4 (10) | 2 (15) | 2 (8) | 0.6 |
| Time on VV-ECMO, days | 18 (14-29) | 24 (16-24) | 17 (14-17) | 0.4 |
| Myocarditis treatment in ICU | ||||
| Corticosteroids | 28 (74) | 7 (54) | 21 (84) | 0.06 |
| Intravenous immunoglobulins | 27 (71) | 8 (61) | 19 (76) | 0.5 |
| Tocilizumab | 0 (0) | 0 (0) | 0 (0) | Na |
| Outcome | ||||
| In-ICU mortality | 5 (13) | 4 (31) | 1 (4) | 0.04 |
| In-hospital mortality | 5 (13) | 4 (31) | 1 (4) | 0.04 |
| 3-month probability of survival, %a | 86 ± 6 | 68 ± 13 | 96 ± 4 | 0.01 |
Values are median (IQR), n (%), or mean ± SD. Continuous variables are compared with Wilcoxon’s rank test; categorical variables are compared with Fisher exact test.
CPR = cardiopulmonary resuscitation; VA-ECMO = venoarterial extracorporeal membrane oxygenation; VV-ECMO = venovenous extracorporeal membrane oxygenation; other abbreviations as in Table 1.
a
Probability of survival were calculated using Kaplan-Meier method and compared with log-tank tests.